This product is a cell metabolite existing in the human body, which can regulate the activity of multiple enzyme systems in glucose metabolism. It is reported that exogenous sodium fructose diphosphate can increase the concentration of adenosine triphosphate and creatine phosphate in cells by activating the activity of phosphofructokinase and pyruvate kinase, promote the influx of potassium ions, and is beneficial to the energy metabolism and glucose utilization of cells under ischemic and hypoxic conditions. It can thus reduce the damage to ischemic myocardium.

This product is a cell metabolite existing in the human body, which can regulate the activity of multiple enzyme systems in glucose metabolism. It is reported that exogenous sodium fructose diphosphate can increase the concentration of adenosine triphosphate and creatine phosphate in cells by activating the activity of phosphofructokinase and pyruvate kinase, promote the influx of potassium ions, and is beneficial to the energy metabolism and glucose utilization of cells under ischemic and hypoxic conditions. It can thus reduce the damage to ischemic myocardium.

This product is an intermediate product of sugar metabolism in the body. It produces pharmacological effects by regulating the activity of several enzymes in sugar metabolism. Exogenous 1,6-diphosphate fructose can increase the concentration of adenosine triphosphate and creatine phosphate in cells, promote the influx of potassium ions, increase the content of diphosphoglycerate in red blood cells, inhibit the release of oxygen free radicals and histamine, and has many other pharmacological effects. It can reduce the damage caused by ischemia and hypoxia, especially for ischemic heart disease.